Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Marker Therapeutics, Inc. (MRKR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.5400+0.2100 (+63.64%)
At close: 04:00PM EDT
0.4985 -0.04 (-7.69%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close0.3300
Open0.6000
Bid0.5100 x 3000
Ask0.5180 x 900
Day's Range0.4900 - 0.6600
52 Week Range0.2500 - 2.1200
Volume74,040,020
Avg. Volume1,568,746
Market Cap45.144M
Beta (5Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-0.5200
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MRKR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Marker Therapeutics, Inc.
    Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
Advertisement
Advertisement